To include your compound in the COVID-19 Resource Center, submit it here.

Europe adds CV risk claims to label for Novo's Victoza

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) said the European Commission approved a label expansion for Type II

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE